Predicting Risk of AMD Progression Using Imaging in Aging Eyes
Official title: Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation - PRIME Study
Run by Singapore National Eye Centre · NCT07653269 · Data updated 2026-11-12
Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 55 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Singapore National Eye Centre Government |
| Locations | 2 sites (Singapore and 1 other locations) |
| Status | Recruiting |
| Started | October 18, 2025 |
| Main results expected | July 31, 2029 |
| Study ends | July 31, 2029 |
| Registry record updated | June 18, 2026 |
| Trial ID | NCT07653269 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 55 and older who can undergo protocol-required eye examinations and multimodal imaging, and who can provide informed consent, are eligible.
✕Probably not a fit
Individuals unable to complete planned imaging or follow-up procedures or with conditions preventing participation may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to understand how early age-related macular degeneration progresses in the community and to identify risk factors that signal progression. It focuses on establishing thresholds for referral and standardizing a community-based screening approach, leveraging multimodal imaging. The study follows participants for up to five years to describe prevalence and natural history, with an emphasis on scalable screening and monitoring in non-hospital settings. No specific interventions are defined within the protocol; the emphasis is on screening and risk stratification to inform future care pathways.
Why it matters
Potential benefit: If successful, the screening approach could enable earlier detection and more personalized monitoring for AMD, potentially delaying vision loss through timely referrals and interventions.
How similar studies have gone: Prior work in diabetic retinopathy demonstrates successful use of standardized screening and referral thresholds; this AMD study seeks to establish analogous community-based thresholds, with more uncertainty around progression patterns.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 55 years or older * No severe systemic illnesses that prevent study participation * Willing and able to undergo protocol-required procedures for both eyes * Willing and able to provide written informed consent Exclusion Criteria: * Systemic disorders that preclude reliable clinical examination or multimodal imaging * Poor compliance or severe mental illness that hinders participation * Persons who are unable to give informed consent
Where it's running
-
Outram Community Hospital
Singapore, Singapore Recruiting -
Singapore National Eye Centre/ Singapore Eye Research Institute
Singapore, Singapore Recruiting
Study contacts
- Study coordinator: Gemmy Cheung Professor
- Email: gemmy.cheung.c.m@singhealth.com.sg
- Phone: +6563224500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Age-Related Macular Degeneration and Its Progression
This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.
-
Blepharoptosis After Repeated Anti-VEGF Injections in One Eye
This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.
-
First-in-human test of ARO-033 in adults
This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.
-
C.001 for retinal degeneration: a first-in-human dose-escalation safety test
A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.
-
Central microperimetry and radial OCT in geographic atrophy
We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.
-
Hyperspectral imaging to map retinal and optic nerve structures
This study will test whether hyperspectral retinal imaging can detect disease-related features in adults with diabetic retinopathy, glaucoma, age-related macular degeneration, and in healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.